S. A. Misek

Germline variation contributes to false negatives in CRISPR-based experiments with varying burden across ancestries

The paper identifies ancestry-related biases in CRISPR experiments caused by germline variants, showing disproportionate effects in cell models from recent African descent.

Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade

This study shows that inhibiting the Rho/MRTF pathway with CCG-257081 enhances the effectiveness of PD1/PDL1 blockade in BRAF-resistant melanoma.

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines

This study shows that inhibiting the Rho/MRTF pathway with CCG-222740 enhances trametinib's effectiveness in NRAS-mutant melanoma cell lines by reducing cell viability and clonogenicity.

E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration

This study identifies E2F1 as a master regulator of metastasis by upregulating Fgf13, which promotes breast cancer cell migration and pulmonary metastasis.

Rho-mediated gene transcription promotes BRAF inhibitor resistance in de-differentiated melanoma cells

This study identifies RhoA-mediated gene transcription as a mechanism of BRAF inhibitor resistance in melanoma, showing that targeting this pathway can re-sensitize resistant cells to vemurafenib.

Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds

This study identifies pirin as the molecular target of the CCG-1423/CCG-203971 compounds, showing its role in modulating MRTF-dependent gene expression and fibrosis.